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Background. The alternative complement pathway (AP) is
activated in individuals with lupus nephritis and in murine mod-
els of systemic lupus erythematosus, including MRL/lpr mice. A
previous study from our laboratory evaluated the development
of renal disease in MRL/lpr mice genetically deficient in factor B
(Bf−/−), a protein necessary for AP activation. MRL/lpr Bf−/−
mice developed less renal disease and had improved survival;
however, these mice were also a different major histocompat-
ibility complex (MHC) haplotype (H-2b) than their wild-type
littermates (H-2k) due to the gene for Bf being located in the
MHC gene complex. We undertook the current study to de-
termine if the decreased renal disease in MRL/lpr Bf−/− mice
was due to the lack of AP activation or the H-2b haplotype by
studying the effects of factor D (Df) deficiency, a critical protein
for AP activation, on disease development in MRL/lpr mice.
Methods. Df-deficient mice were backcrossed with MRL/lpr
mice for four to nine generations. MRL/lpr H-2k Df−/−, Df+/−,
and Df+/+ littermates were evaluated for disease development.
Lack of AP activation in MRL/lpr Df−/− mice was determined
by the zymosan assay. Serum creatinine levels were measured
using a creatinine kit. Proteinuria and autoantibody levels were
determined by enzyme-linked immunosorbent assay (ELISA).
Sections from one kidney were stained with fluorescein isothio-
cyanate (FITC) a-murine C3 or a-murine IgG to detect C3 and
IgG deposition. The remaining kidney was cut in half with one
half fixed, sectioned, and stained with hematoxylin and eosin
and periodic acid-Schiff (PAS) to evaluate pathology and an-
other half fixed in glutaraldehyde and examined via electron
microscopy.
Results. MRL/lpr Df−/− mice had similar glomerular IgG
deposition, proteinuria and autoantibody levels, as Df+/+ and
Df+/− littermates. However, glomerular C3 deposition, serum
creatinine levels, and pathologic renal disease were significantly
reduced in Df−/− mice. Despite the lack of renal disease in
Df−/− mice, life span was not impacted by factor D deficiency.
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Conclusion. The absence of Df and AP activation is protec-
tive against the development of proliferative renal disease in
MRL/lpr mice suggesting the similar effect of Bf deficiency in
MRL/lpr mice was also due to the lack of AP activation.
The complement system is a major effector of the hu-
moral branch of the immune system and is a first line
of defense against infection. Complement activation is
initiated via three different pathways: the classical, the
lectin, and the alternative pathways [1]. Activation of the
alternative pathway (AP) of complement is believed to
be important in the initial immune response to invading
microorganisms. Two proteins involved in the activation
of complement that are exclusive to the AP are factor
D (Df) and factor B (Bf). AP activation is initiated by
C3 tickover followed by deposition of C3b on a pathogen
surface. Bf binds to deposited C3b and is cleaved by D to
form the AP C3 convertase C3bBb, resulting in increased
cleavage of C3 and the increased formation of C3a and
C3b. C3bBb binds an additional molecule of C3b to form
the AP C5 convertase C3bBbC3b for the cleavage of C5
into C5a and C5b. C5b deposition is the initial step in
the formation of the membrane attack complex (MAC),
the result of which is cell lysis. Df is produced mainly
by adipocytes and is essential for formation of the AP
C3 convertase, which is central to the amplification of
complement activation not only through the AP but also
for the classical and lectin pathways. Complement activa-
tion, either through the classical or AP, plays a key role in
the pathogenesis of glomerulonephritis in systemic lupus
erythematosus (SLE) [2–5].
SLE is a multisystem chronic inflammatory disease of
unknown etiology. This autoimmune disorder is char-
acterized by the production of antinuclear antibodies,
arthritis, vasculitis, and glomerulonephritis [6]. Con-
tributing to the development of glomerulonephritis is the
deposition of immune complexes in the glomeruli of indi-
viduals with SLE. This IC deposition leads to complement
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activation, formation of the inflammatory mediators C3a
and C5a, and MAC formation [3–5]. The AP is thought
to contribute to tissue damage via the C3 amplification
loop. AP activation increases the concentration of inflam-
matory mediators and the number of MAC complexes
deposited in tissue. Deposition of these complexes and
increased levels of complement split products are seen in
persons with lupus nephritis [3–5, 7, 8]. In addition, both
C3a and C5a act as anaphylatoxins while C5a also acts as
a chemoattractant, recruiting neutrophils [9] and other
immune cells [10] to the site of inflammation.
Previous studies in our laboratory investigated the role
of complement in the development of renal disease in the
murine model of SLE, the MRL/lpr mouse (now des-
ignated MRL/MpJ-Tnfrsf6lpr). MRL/lpr mice typically
succumb to a lupus-like syndrome, including glomeru-
lonephritis and kidney failure at 6 to 8 months of age
[11]. Watanabe et al [12] demonstrated that MRL/lpr
mice genetically deficient in Bf (Bf−/−) developed less
proteinuria and pathologic renal disease than wild-type
littermates. In addition to a lack of AP activation and
Bf production; however, the Bf−/− mice differed from
their wild-type littermates at the major histocompatibility
complex (MHC) locus having the H-2b haplotype instead
of the H-2k haplotype found in wild-type MRL mice. The
gene encoding Bf lies within the class III region of the
MHC locus. Prior gene mapping studies in MRL/lpr mice
found no link between MHC haplotype and development
of renal disease [13, 14]. Thus, although we believed it un-
likely MHC was a key factor, it was nonetheless unclear
whether the protective effect seen in the Bf−/− mice was
due to the lack of AP activation or the H-2b haplotype.
To determine if inhibition of the alternative pathway
of complement was responsible for the decreased in-
cidence of renal disease in MRL/lpr Bf−/− mice, Df-
deficient mice [15] were backcrossed to MRL/lpr mice
for four to nine generations. Sera from MRL/lpr mice
lacking Df demonstrated no AP activity in response
to zymosan. Results reported herein demonstrate that
pathologic and functional renal disease were significantly
reduced in Df−/− mice confirming that the AP plays a sig-
nificant role in the proliferative glomerulonephritis that
develops in MRL/lpr mice.
METHODS
Study mice
Df-deficient mice were derived on the 129/B6 back-
ground as previously described [15]. Mice heterozygous
for Df were interbred for four to nine generations with
MRL/MpJ-Tnfrsf6lpr (MRL/lpr) mice (Jackson Labora-
tories, Bar Harbor, ME, USA). At backcross 4 and 9,
mice heterozygous for Df were bred to produce wild-
type (Df+/+), heterozygous (Df+/−) and Df-deficient
(Df−/−) MRL/lpr mice. Mice in groups of 30 (15 male
and 15 female) for each genotype were studied at back-
cross 4 while groups of eight to nine mice of each geno-
type were studied at backcross 9. Mice were maintained
in the animal facility at the Ralph H. Johnson VA Medical
Center under specific pathogen-free conditions. Routine
screening of the mice for murine pathogens was negative.
An age matched group of 10 BALB/c mice and 10 MRL/
lpr mice (both from Jackson Laboratories) were in-
cluded in the study as negative and positive controls,
respectively.
Genotyping of mice by polymerase chain
reaction (PCR)
Primers for PCR for Df were as follows: 5fD, 5′-
GCGATGGTATGATGTGCAG-3′; 3fD, 5′-GGTTGCT
CTCTGCACACAT-3′; and 3NEOfD, 5′-GGCCGAT
CCCATATTGGC′-3. DNA from tail snips was isolated
using a DNeasy kit (Qiagen, Valencia, CA, USA). PCR
was performed using 500 ng of DNA in a 25 lL reaction
containing 2 mmol/L MgCl2, 0.2 mmol/L desoxynucle-
oside triphosphate (dNTP) (Perkin Elmer, Boston, MA,
USA), 1.67 units of Taq polymerase (Qiagen) and 60 pmol
of each primer. PCR conditions were as follows: 94◦C
for 5 minutes; 30 cycles of 94◦C for 1 minute, 7◦C for 1
minute, 72◦C for 1 minute; and 72◦C for 10 minutes. PCR
products were electrophoresed in a 2% agarose gel and
visualized by ethidium bromide staining [15]. All mice
were confirmed as fas−/− and H-2k/k at the MHC locus
as previously described [12].
The study mice were also genotyped at an additional
25 microsatellite markers differing between MRL and
B6/129 emphasizing loci linked with disease [14]. Specific
markers used will be provided on request. As expected
at the F4 generation the study mice were over 80% MRL
genotype at these loci. There were no significant differ-
ences in genotype between Df+/+ and Df−/− mice at
these loci. Backcross 9 mice were genotyped at fas, H-2
and Df loci only but are assumed to be greater than 99%
MRL genotype.
Df production
The absence of serum Df in Df-deficient mice was con-
firmed by Western blot analysis. Briefly, sera were run
on an 8% to 16% Tris HCL gel (BioRad, Hercules, CA,
USA), transferred to a nitrocellulose (Immobilon; Milli-
pore, Bedford, MA, USA) membrane and blocked with
5% milk. After washing, Df was detected by incubation
with an affinity-purified rabbit antimouse Df antibody
[15], followed by incubation with an alkaline phosphatase
conjugated goat antirabbit antibody (Southern Biotech,
Birmingham, AL, USA). Bound Df was visualized us-
ing the enhanced chemiluminescence (ECL) chemi-
luminescent detection system (Amersham Pharmacia,
Piscataway, NJ, USA) and scanned using a Storm
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860 Phospho Imager (Molecular Dynamics/Amersham
Pharmacia).
Ap activation
Lack of AP activation was determined by C3 depo-
sition on zymosan as previously described [16]. Briefly,
zymosan A (Sigma Chemical Co., St. Louis, MO, USA)
was suspended at 0.4 mg/mL and activated by boiling in
normal saline. Zymosan particles (106) were incubated at
37◦C for 15 minutes with 10 lL of pooled mouse serum
in GVB2+ (Sigma Chemical Co.) containing 10 mmol/
L ethyleneglycol tetraacetate (EGTA) in a final reac-
tion volume of 100 lL. Particles were then washed with
ice-cold phosphate-buffered saline (PBS) containing 1%
bovine serum albumin (BSA) and 5 mmol/L ethylenedi-
aminetetraacetic acid (EDTA). Bound C3 was detected
by using fluorescein isothiocyanate (FITC)-conjugated
F(ab)2 fragments of goat antimouse C3 IgG (25 lg/mL)
(Cappel, Aurora, OH, USA) on a FACScan flow cytome-
ter (Becton Dickson, San Diego, CA, USA). In a re-
constitution assay, purified human Df (Sigma Chemical
Co.) was added to the Df-deficient serum at 0.5 lg/mL of
mouse serum. A reaction mixture of Df-sufficient serum
containing 10 lmol/L EDTA served as a negative control.
Evaluation of autoantibody production
A rabbit kidney preparation was used for the detection
of antibodies to glomerular antigens (GA) and was pre-
pared as previously described [17]. Briefly, kidneys were
harvested from New Zealand White rabbits and pressed
through a 75 lm sieve. The GA was washed 2× with ster-
ile ice-cold PBS. After the last wash, PBS was decanted
and the GA was lyophilized, resuspended by sonication
in PBS, and stored at 4◦C until use.
Sera were assayed for the presence of antibodies to
double-stranded DNA (dsDNA), antibodies to GA and
for the presence of rheumatoid factors (RF) of the IgM
and IgG isotype by enzyme-linked immunosorbent as-
say (ELISA) as previously described. Briefly, 96 well mi-
crotiter plates (Dynex, Chantilly, VA, USA) were coated
with the respective antigen diluted to the appropriate
concentration as previously determined for each assay:
calf thymus (CT) dsDNA (Sigma Chemical Co.) 5 lg/mL
in standard saline citrate (SSC) buffer, rabbit GA (see
above), 40 lg/mL in PBS and rabbit IgG (Sigma Chemi-
cal Co.), 1 lg/mL in carbonate/bicarbonate buffer, pH 9.6.
Sera were applied to the plates with a starting dilution of
1:100 in PBS-Tween 1% BSA. After washing, the plates
were incubated with goat antimouse IgGc -specific anti-
body (Sigma Chemical Co.) conjugated to horseradish
perioxidase for detection of antibodies to dsDNA, GA,
and RF of the IgG isotype. For IgM RF, goat anti-
mouse IgM (Southern Biotech) horseradish peroxidase
conjugate was used. Plates were than developed using
tetramethylbenzidine (TMB) (Sigma Chemical Co.) and
the resulting absorbance was read at 380 nm on a spec-
tophotometer (Titertek, Huntsville, AL, USA). Pooled
MRL/lpr sera was used as a positive control. BALB/c
sera served as a negative control.
Renal pathology
For evaluation of renal pathology, mice were anes-
thetized by inhalation of isofluorane and euthanized by
cervical dislocation at 20 weeks of age for backcross 4
and 28 weeks of age at backcross 9. One kidney was
halved and fixed in 10% buffered formalin, imbedded
in paraffin, and sectioned before staining with periodic
acid-Schiff (PAS) or hemotoxylin and eosin. Slides were
read and interpreted in a blinded fashion, grading the
kidneys for polymorphonucleocyte infiltration (0 to 1+),
hypercellularity (0 to 3+), crescent formation (0 to 2+),
and necrosis (0 to 2+), thickened basement membrane
(0 to 2+), and epithelial reactivity (0 to 1+). Interstitial
changes and vasculitis were also noted. Scores of these
features were then added together to yield a total renal
score with a maximum of 15 [13]. Scores for crescents and
necrosis were multiplied by 2 prior to adding to the over-
all score similar to the NIH lupus activity score to reflect
the severity of these lesions.
The other half kidney was placed in glutaraldehyde
prior to being processed for analysis by electron mi-
croscopy. The electron microscopic pictures were inter-
preted by standard techniques again in a blinded fashion
evaluating for degree and location of immune complexes.
Renal IgG and C3 deposition
The remaining kidney from each mouse was snap
frozen in liquid nitrogen2 and stored at −70◦C. Kidneys
were then cut in 4 um slices, mounted on slides, and incu-
bated with goat antimouse IgG FITC-conjugated or goat
antimouse C3 FITC-conjugated antibodies (both from
ICN). Slides were evaluated in a blinded fashion and
scored according to the glomerular fluorescence in each
section 0 to 3+ (1+, mild staining; 2+, moderate staining;
3+, high staining).
Measurement of proteinuria
Mice were placed in metabolic cages and urine was col-
lected over a 24-hour period. Urinary albumin was mea-
sured by ELISA, as previously described [12]. Briefly,
microtiter plates were coated with goat antimouse al-
bumin (R&D Systems, Minneapolis, MN, USA) and
blocked with 0.25% gelatin (type A from porcine skin)
(Sigma Chemical Co.) in PBS. Urine samples were ap-
plied to the plates starting with a 1:100 dilution in PBS-
Tween 0.25% gelatin. Mouse albumin in the sample was
detected using a goat antimouse albumin horseradish pe-
rioxidase (R&D Systems) and TMB. Absorbencies were
read at 380 nm and the amount of mouse albumin in each
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sample was calculated by comparison with standards of
known concentration.
Determination of serum creatinine
Serum creatinine levels were measured by the alkaline
picric acid method with a creatinine kit (Sigma Chemical
Co.) according to the manufacturer’s instruction. Mea-
surements were performed on sera obtained at 10 and
20 weeks of age. Measurement at 10 weeks of age (prior
to disease onset) was considered to be the basal level.
Statistical analysis
Statistical significance was determined by one-way
analysis of variance (ANOVA), or Student t where appro-
priate, using Prism 3.0 Graphpad Software. For ANOVA
post hoc analysis, the Mann Whitney U test was used with
a P < 0.05 being considered significant.
RESULTS
Physiologic appearance
MRL/lpr H-2k mice deficient in Df (Df−/−) at the
backcross 4 generation were weighed and examined on
a weekly basis [15]. Mice at the backcross 9 generation
were examined weekly, but not weighed. There were no
significant differences in the weights of the mice in the
three groups during the period of observation (data not
shown). MRL/lpr mice develop skin rash and ear necro-
sis with age as part of their systemic autoimmune disease.
The development of skin rash and/or ear necrosis was
present beginning at 14 weeks of age and was similar in
severity, percent of mice involved, and age of onset for
all three groups as graded on a weekly basis in both the
backcross 4 and 9 generations (data not shown). There
was no significant difference in spleen or spleen/body
weight ratios between the groups (data not shown) in-
dicating no profound effect of Df deficiency on the sig-
nificant splenomegaly that develops in MRL/lpr mice.
Df production and alternative pathway activation
To verify that the phenotype matched the genotype in
MRL/lpr Df−/− mice, we performed Western blot analy-
sis on sera from the backcross 4 MRL/lpr Df+/+, Df+/−,
and Df−/− mice. Df was not detected in the serum of
Df−/− mice by Western blot analysis, but was present in
the sera of the Df+/+ and Df+/− littermates (Fig. 1A). To
confirm that the Df−/− mice lacked activation of the AP,
sera from backcross 4 and 9 MRL/lpr mice were tested for
C3 deposition on zymosan, a component of yeast cell wall
that activates the AP of complement. Results presented
are from backcross 4 mice, although similar results were
obtained with sera from backross 9 mice. Sera from litter-
mates sufficient in Df showed AP activation via C3 depo-
sition on zymosan in buffer containing Mg2+/EGTA. C3
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Fig. 1. Absence of factor D (Df) and activation of the alternative com-
plement pathway (AP) in MRL/lpr Df−/− mice. (A) Western blot
of serum to detect Df−/−. There is no detectable Df in the serum of
Df−/− mice. It is present in the heterozygous and wild-type littermates.
(B) Flow cytometric analysis shows C3 is deposited on zymosan as evi-
dence of AP activation in the pooled serum of wild-type mice incubated
with Mg2+ and ethylene glycol tetraacetate (EGTA) to prevent classicl
complement activation (upper left). AP activation in wild type sera is
inhibited by the addition of ethylenediaminetetraacetic acid (EDTA)
(upper right). Deposition of C3 on zymosan is not detected in the pooled
serum of Df−/− littermates when incubated with Mg2+ and EGTA
(lower left). C3 deposition is detected as AP activation is restored in
serum from Df−/− mice upon addition of human factor D (lower right).
deposition on zymosan was absent in the pooled sera from
Df−/− mice in Mg2+/EGTA, but was restored upon ad-
dition of human Df (Fig. 1B). These results indicate that
the MRL/lpr mice deficient in Df lacked activation of the
AP despite having a functional AP upon addition of Df.
Autoantibody production
Autoantibody production is a hallmark of SLE and dis-
ease development in MRL/lpr mice. To determine if the
lack of Df and AP activation affected autoantibody pro-
duction, autoantibody levels were evaluated at 2-week
intervals between 10 and 20 weeks of age in the back-
cross 4 mice. The development of antibodies to dsDNA
(Fig. 2A), GA, and RF of the IgM isotype (data not
shown) did not differ significantly between the Df+/+,
Df+/−, and Df−/− MRL/lpr mice at any age. However,
by 20 weeks of age, both Df+/− and Df−/− mice had
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Fig. 2. Serum levels of anti-double-stranded (ds)DNA and IgG
rheumatoid factor antibodies in MRL/lpr Df−/− mice. Serum levels
of anti-dsDNA do not differ significantly between MRL/lpr Df+/+,
Df+/−, and Df−/− littermates. In contrast, MRL/lpr Df−/−, and
Df+/− mice develop significantly higher levels of IgG rheumatoid fac-
tor compared to wild-type littermates at 20 weeks of age (P < 0.01 and
P < 0.05 respectively). Sera shown at 1:100 dilution (N = 18–30 mice in
each group). Inset graphs show additional dilutions of sera at 20 weeks
of age.
significantly higher levels of IgG RF (Fig. 2B) than their
wild-type littermates (P < 0.01 and P < 0.05, respec-
tively).
Proteinuria
The mean level of albumin (mg/mouse/day) increased
with age for Df+/+, Df+/−, and Df−/− MRL/lpr mice in
both the backcross 4 and 9 groups. The BALB/c (negative
control) showed no increase in proteinuria. The mean
level of albuminuria and the percentage of mice excreting
greater than 1 mg/day were similar between the groups
at all ages (Fig. 3A and B). There was also no difference
in the age at onset of albuminuria between the groups.
Serum creatinine levels
Serum creatinine levels were measured at 10 and
20 weeks of age in the backcross 4 mice (Fig. 3C). Serum
creatinine levels rose significantly for Df+/+ and Df+/−
mice during this time interval. Levels of serum creatinine
at 20 weeks of age were significantly higher for Df+/+
and Df+/− mice compared to the level in Df−/− mice
(P < 0.05). The concentration of serum creatinine did not
increase significantly for Df−/− mice from 10 to 20 weeks
of age, indicating preservation of renal function in Df−/−
mice.
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Fig. 3. Proteinuria and serum creatinine in MRL/lpr mice. A 24-hour
albumin excretion was determined by enzyme-linked immunosorbent
assay (ELISA). Levels of albumin in the urine were not significantly
different between the genotypes at any age tested for (A) backcross
4 (N = 18–30 mice/group) or (B) backcross 9 (N = 6–8 mice/group).
(C) The concentration of serum creatinine in backcross 4 mice did not
differ significantly between the groups at 10 weeks of age. At 20 weeks,
the factor D (Df) Df+/+ and Df+/− mice had significant (∗∗P < 0.01)
increases in serum creatinine while the levels in Df−/− mice did not
increase significantly from basal levels or the BALB/c negative control.
Similar results are seen with the backcross 9 mice at 28 weeks of age.
∗P < 0.05. BC is backcross, ND is not done.
IgG and C3 deposition in the kidneys
IgG and C3 deposition in the kidneys is associated with
glomerulonephritis in MRL/lpr mice. To determine if the
lack of Df and AP activation would affect glomerular
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Fig. 4. Kidney pathology and kidney deposition of IgG and C3. Im-
munofluorescent staining of IgG and C3 deposition show that glomeru-
lar IgG deposition occurred similarly in factor D (Df) Df−/− (A) and
Df+/+ mice (B). Deposition of C3 in the kidneys of Df−/− (C) is
decreased in Df+/+ (D) mice. To assess pathologic changes, kidney
sections were stained with periodic acid-Schiff (PAS) (E and F) and
hemoatoxylin and eosin (G and H). Sections from Df+/+ and Df−/−
mice are shown. (E) Df−/− PAS; normal glomerulus, clear Bowman’s
capsule (black arrow), clear vascular spaces (white arrow), normal tuft
architecture. (G) Df−/− H&E; normal glomerular structure (black and
white arrows). (F) Df+/+ PAS; crescent formation (white arrow), fo-
cal hypercellularity (black arrow). (H) Df+/+ hematoxylin and eosin;
hypercellularity (black arrow), mesangial matrix expansion, no clear
vascular space visible, beginning crescent formation (white arrow).
deposition of IgG and C3, anti-IgG, and anti-C3 FITC-
conjugated antibodies were used to detect the presence of
IgG and C3 in the kidneys of Df+/+, Df+/−, and Df−/−
backcross 4 (Fig. 4) (Table 1) and Df+/+and Df−/−back-
cross 9 mice (Table 1). MRL/lpr mice deficient in Df had
similar levels of glomerular IgG deposition in the kidneys
(Fig. 4A) as their wild-type (Fig. 4B) and heterozygous
littermates (Table 1). Despite the similar levels of IgG de-
position in the two groups, significantly less C3 deposition
was detected in the glomeruli of Df−/− mice (Fig. 4C)
compared to Df+/+ (Fig. 4D) and Df+/− littermates at
the backcross 4 and Df+/+ and Df−/− backcross 9 gener-
ations (Table 1) (P < 0.01). The decreased C3 deposition
in the Df−/− mice paralleled the absence of alternative
complement pathway activation in these mice.
Renal pathology
To determine the effect of the Df knockout on the
development of pathologic kidney disease in MRL/lpr
mice, mice from each genotype (Df+/+, Df+/−, and
Df−/−) at backcross 4 were sacrificed at 20 weeks of age.
Pathologic changes in the kidneys were assessed by light
microscopy using the scoring system described in the
Methods section. Df−/− mice scored lower for all indi-
vidual aspects of kidney pathology evaluated compared
to Df+/+ and Df+/− littermates, including a significant
decrease in glomerular hypercellularity. Figure 4E to H
show PAS- and hematoxylin and eosin–stained sections
of kidneys from Df+/+ and Df−/− mice. Overall, Df−/−
mice had normal glomeruli (Fig. 4E) with a clear Bow-
man’s capsule (black arrow), clear vascular spaces (white
arrow) and normal glomerular tuft architecture. Hema-
toxylin and eosin staining of Df−/− kidneys (Fig. 4G) also
demonstrated normal glomerular structure and clear vas-
cular spaces (arrows). In contrast, Df+/+ mice had dif-
fuse glomerular disease with severe proliferative pathol-
ogy. PAS staining of Df+/+ kidneys showed mesangial
matrix expansion, hypercellularity (Fig. 4F, black arrow),
and cresent formation (Fig. 4F white arrow). Hema-
toxylin and eosin staining of kidneys from Df+/+ mice
also revealed the occurrence of focal hypercellularity
(Fig. 4H, black arrow) with crescent formation (Fig. 4H,
black arrow). The overall pathologic scores (Table 1)
were significantly lower for backcross 4 Df−/− mice com-
pared to wild-type littermates at 20 weeks of age (P =
0.006). There were no notable differences in tubular in-
flammation or vasculitis. Backcross nine mice were al-
lowed to age until 28 weeks of age. Pathologic assessment
of kidney disease at 28 weeks showed less severe renal dis-
ease in the backcross 9 Df knockout mice similar to that
seen in the backcross 4 20-week-old Df-deficient mice.
The difference in pathologic renal disease at the 28-week
time point approached (P = 0.08) but did not reach signif-
icance primarily due to the presence of minimal disease
in one of the wild-type mice (renal score of 3) (Table 1).
The numbers of mice studied at the 28-week time point
were small due to significant loss due to death between
20 and 28 weeks in both groups.
Electron microscopy
Examination of renal sections by electron microscopy
revealed no differences between backcross 4 Df +/+ and
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Table 1. Immunofluorescencea and pathologyb
IgG C3 Kidney pathology scores
Genotype BC4 BC9 BC4 BC9 BC4 BC9
Df+/+ 1.33 ± 0.16 2.2 ± 0.37 2.07 ± 0.18 2.4 ± 0.40 8.53 ± 1.2 9.5 ± 2.2
Df+/− 1.23 ± 0.13 ND 1.75 ± 0.16 ND 5.08 ± 0.7 ND
Df−/− 1.00 ± 0.19 1.83 ± 0.46 0.42 ± 0.16∗ 0.67 ± 0.11∗ 3.1 ± 0.6∗∗ 5.5 ± 0.7
Df is factor D; BC is backcross; ND is not done.
aGlomerular IgG and C3 deposition was graded based on the amount of immunofluorescence on a scale from 0 to 3+ by a blinded observer. Data are the mean
± SE of the graded immunofluorescence. Similar IgG deposition was observed in the glomeruli of all three genotypes. In contrast, Df−/− mice had significantly less
glomerular C3 deposition than Df+/+ and Df+/− littermates. ∗P < 0.01.
bKidneys were scored as in the Methods section. Mean pathology scores are shown for backcross 4 mice ± SEM. ∗∗P = 0.006 in Df−/− mice when compared to
wild-type littermates.
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Fig. 5. Survival of factor D (Df)-deficient mice. Combined survival is
shown for BC4 (10 to 22 months) and BC9 (20 to 28 weeks) mice. There
was no significant difference in the survival rate of the Df-deficient
MRL/lpr mice compared to wild-type and heterozygous littermates.
Df −/− mice as to location of immune complexes or
podocyte foot process fusion. All mice, regardless of
genotype, manifested primarily subendothelial deposits,
lesser subepithelial deposits, and podocyte effacement
(data not shown).
Survival
Despite the marked difference in renal disease be-
tween the two groups of mice, there was no difference
in overall survival (Fig. 5).
DISCUSSION
To further define the role of the complement alter-
native pathway in the development of renal disease in
MRL/lpr mice, we backcrossed the Df-deficient genotype
onto the MRL/lpr lupus prone genetic background. As
described in the Results section, serum from MRL/lpr
mice deficient in Df lacked activation of the AP. The re-
sults presented herein indicate that the lack of Df and AP
activation had no significant effect on the development
of skin disease, splenomegaly, proteinuria, production of
antibodies to dsDNA and GA, or glomerular IgG depo-
sition. MRL/lpr Df−/− mice were, however, protected
against the development of pathologic renal disease likely
secondary to reduced/absent glomerular C3 deposition.
MRL/lpr Df−/− mice also maintained normal renal func-
tion as measured by serum creatinine indicating a critical
role in these mice for the alternative complement path-
way in the development of proliferative renal disease and
renal dysfunction.
Our previous studies in MRL/lpr mice deficient in the
alternative complement pathway Bf also demonstrated
that inhibiting AP activation is protective against the
development of renal disease [18]. The current studies
were undertaken to confirm the renal protective effect
of blocking the alternative complement pathway. Further
confirmation of the effect of blocking the alternative com-
plement pathway in MRL/lpr mice was warranted as the
MRL/lpr Bf−/− mice differed from their wild-type lit-
termates in being Bf deficient as well as possessing the
H-2b MHC haplotype. MRL/lpr wild-type mice are H-
2k. Prior studies of genetic susceptibility loci in MRL/lpr
mice found no linkage between MHC and any disease
parameter, although the role of the MHC in disease in
MRL/lpr has never been directly studied. Based on the
lack of evidence for a role for MHC in disease in MRL/lpr
mice, we hypothesized that the decreased renal disease
seen in the Bf-deficient MRL/lpr mice was due to the
lack of alternative pathway activation rather than MHC
effects. The renal protective effect of Df deficiency in
MRL/lpr mice supports this hypothesis.
Thus, considered together these studies indicate that
the most likely mechanism for the decreased renal dis-
ease in MRL/lpr Bf−/− and Df−/− mice was the lack
of AP activation and the amplification loop. In relating
these studies to human disease, activation of the alterna-
tive complement pathway is associated with pathologic
renal disease in human SLE as well [2–5]. Lupus nephri-
tis, however, is not the only disease where the alternative
complement pathway appears to play a major role. A
number of studies are finding profound effects of block-
ing the alternative complement pathway in a variety of
inflammatory and renal diseases [19–23]. We recently re-
ported the protective effect of Bf deficiency on ischemic
acute renal failure in mice [24]. Others have reported
beneficial effects of blocking the alternative complement
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pathway on reperfusion injury [25–29]. Thus, blocking the
alternative complement pathway may prove a useful ther-
apeutic intervention in many diseases where complement
activation plays a pathogenic role.
The mechanism for the protective role in lupus nephri-
tis of blocking the alternative complement pathway is not
clear from the current studies. The lack of C3 deposition
in the kidneys of the Df-deficient mice suggests a critical
role of the alternative pathway in C3 activation and depo-
sition of C3 in immune complexes; other mechanisms may
also be operant, however. Previous studies demonstrated
local production of both Bf and C3 in the kidney in lupus
mice [30, 31]; it is unknown if similar local production of
Df occurs in the kidney. The role and/or importance of
this local production of complement proteins in inflam-
matory reactions are unclear. Indeed, whether the renal
protection noted in this study was due to a local effect
within the kidney or via blocking systemic complement
activation is unknown.
Alterations in autoantibody production modulate dis-
ease in MRL/lpr mice [11]. Although complement ac-
tivation is critical for the development of T-dependent
antibody responses and the anti-dsDNA response is T
dependent, there was no effect of Df deficiency on au-
toantibody production. Thus, AP activation is not nec-
essary for the production of autoantibodies in MRL/lpr
mice. The increased IgG RF production in the Df+/− and
Df −/− backcross 4 mice was unexpected and unlikely of
clinical significance given that there was only a one titra-
tion difference. This difference in RF production was not
present in the backcross 9 mice (data not shown). There
was no difference in RF production between the Bf−/−
mice and wild-type mice indicating that AP activation is
not a key mediator of RF production.
IgG3 cryoglobulin production is another key
pathogenic antibody response in MRL/lpr mice.
The Bf−/− mice had decreased IgG3 cryogloulin levels
compared to wild-type mice. Subsequent studies in our
laboratory have determined the differences in IgG3
production are due to H-2 differences and not the levels
of Bf production (Sekine, Gilkeson, unpublished data).
Df-deficient mice had similar serum IgG3 levels as their
wild-type littermates (data not shown) indicating that
the alternative complement pathway is not critical to
IgG3 isotype switching.
In contrast to MRL/lpr Bf−/− and Df−/− mice, stud-
ies in MRL/lpr mice lacking C3, the central protein in
all three complement pathways, were not protected from
renal disease and had significantly increased proteinuria
compared to wild-type littermates [18] (Table 2). We hy-
pothesized prior to that study that knocking out C3 would
prevent renal damage in MRL/lpr mice caused by activa-
tion of the classic and alternative pathways. Autoanti-
body production in MRL/lpr C3−/− mice did not differ
significantly from that in wild-type littermates, indicating
Table 2. Comparison of the affect of complement knockouts on
disease development in MRL/lpr mice
Genotype (major
histocompatibility
complex haplotype) Bf−/−(H-2b) Df−/−(H-2k) C3−/−(H-2k)
Proteinuria
Renal score
Glomerular C3 —
deposition
Glomerular IgG
deposition
dsDNA Ab
Sera IgG3
Sera C3 —
, no difference, , increased, , decreased compared to wild-type MRL/lpr
mice. See text for discussion. —, Not detected.
again complement activation is not crucial for the produc-
tion of autoantibodies to dsDNA, GA, or RF in MRL/lpr
mice. IgG deposition in the kidneys of MRL/lpr C3−/−
mice was significantly increased compared to wild-type
littermates. We believe these observations demonstrate
the importance of the classic complement pathway in
the clearance of glomerular immune complexes. We hy-
pothesized that the loss of the classical pathway of com-
plement impaired an immune complex clearance system
that was already overwhelmed [32], leading to a marked
retention of immune complex in the glomeruli. With
increased deposition and retention of IgG, Fcc /Fcc R
interactions would likely be increased and prolonged, in-
creasing FcRc stimulation and activation of mesangial
cells as well as infiltrating macrophages [10, 33]. In con-
trast, MRL/lpr Bf- and Df-deficient mice demonstrate
that inhibition of the AP, while leaving the CP intact, is
beneficial in lupus nephritis despite glomerular IgG de-
position and FcRc mediated effects.
The disconnect between proteinuria and proliferative
glomerular disease in this study was present at both the
backcross 4 and backcross 9 generations. The mechanism
for this “disconnect” is unclear, but proteinuria in the
Df−/− mice likely reflects the presence of subepithelial
IgG deposition and podocyte effacement which was not
affected by Df deficiency. In contrast, the lack of alter-
native complement activation did prevent glomerular C3
deposition and subsequent glomerular proliferation and
inflammatory cell ingress. Further studies are warranted
to fully define the mechanism for the renal protective ef-
fect noted in both Bf- and Df-deficient mice.
A number of complement component knockout mice
are available to study the role of complement in health
and disease [15, 34–40]. Knocking out complement com-
ponents involved in the early activation phase of the
classic pathway leads to the development of a lupus-like
syndrome in nonautoimmune mice [34, 41]. These find-
ings parallel observations in humans where deficiency of
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C1q is a risk factor for the development of SLE [42]. The
loss of early AP components such as Df, although linked
to susceptibility to Neisseria infections, is not associated
with the development of autoimmune disease [43]. The
deficiency of inhibitory proteins for the AP (i.e., factor
H) is often accompanied by renal disease in humans [44].
Factor H is a glycoprotein that plays a pivotal role in
the control of AP activation. Factor H acts as a cofac-
tor for factor I in the degradation of newly formed C3b
molecules and destabilizes the AP C3 convertase C3bBb
[1]. Recent studies by Pickering, et al [45] reported the
development of similar membranoproliferative renal dis-
ease in mice deficient in factor H. These studies further
support the involvement of the AP in the pathogenesis of
inflammatory renal disease. Blocking later complement
factors using antibodies specific for C5 [46] was success-
ful as a therapeutic intervention to prevent the develop-
ment of lupus nephritis, confirming the utility of therapies
aimed at inhibition of specific complement proteins.
One limitation of a study in mice studied at the fourth
backcross generation is that the background of the mice
is only 80% MRL. We performed the initial studies at
this backcross generation in order to do a direct compar-
ison with the Bf-deficient MRL/lpr mice that were also
studied at the fourth backcross generation. Although the
lack of complete genetic homogeneity could affect results
due to random genetic combinations, we believe this ef-
fect is limited in the results reported herein due to the
large number of mice studied and the screening of ad-
ditional microsattelite markers to ensure comparability
of the study groups. Although similar effects on renal
disease were observed in the backcross 9 mice, the differ-
ence in the mean pathology score between the wild-type
and Df-deficient mice did not reach statistical significance
(P = 0.08). By 28 weeks, the number of mice declined
due to deaths in each group. This likely resulted in selec-
tion of mice with less severe disease. Evidence for this is
given by the lack of a significant increase in the scores for
the wild-type mice from backcross 4 at 20 weeks and the
backcross 9 at 28 weeks. These data also suggest that with
aging, despite the continued block of C3 activation via the
AP, the protective effect against proliferative renal dis-
ease decreases. The significantly lower serum creatinine
levels in the backcross 9 Df knockout mice at 28 weeks
of age suggest that the differences in renal scores at this
time point, although not statistically significant, were of
clinical significance. The evaluation of disease develop-
ment in MRL/lpr Df−/− backcross 4 mice was carried
out at 20 weeks of age to assess effects at maximum dis-
ease activity while the backcross 9 mice were studied at
28 weeks to allow study effects of Df deficiency in mice
with more advanced disease development. MRL/lpr mice
show signs of disease as early as 16 weeks and on average
have a 50% mortality by 22 to 24 weeks of age, a mortality
rate we observed in the backcross 9 mice. We decided to
end the backcross 9 study at 28 weeks due to the mortal-
ity rate observed at that time point. Differences in time
of death for MRL/lpr mice between the Df and Bf stud-
ies likely reflect the different breeding strategies used. In
the Bf study, female mice were used for breeding as long
as they were productive. This may have led to selection
of longer-lived mice by using mice that were the fourth
or fifth litter of a specific female. In the current study,
only the first litter of a mother was used to eliminate this
possible bias. Although there were these differences in
longevity in wild-type mice between the Bf and Df stud-
ies perhaps due to breeding strategies, the effects on renal
disease are consistent across studies.
CONCLUSION
The lack of the AP of complement due to Df deficiency
has a consistent and significant protective effect on the
development of proliferative renal disease in MRL/lpr
mice. These results support our prior findings of renal
protection in Bf-deficient MRL/lpr mice that also lack
AP activation, but in addition, the studies reported herein
are able to define complement dependent versus H-2–
dependent effects on disease [12]. In addition to protect-
ing against lupus-like renal disease, blocking activation
of the AP is also protective against other models of tissue
injury caused by complement activation [19–23]. Based
on these results, blocking AP activation may be an effec-
tive therapeutic strategy for glomerulonephritis in SLE.
Blocking AP activation is an attractive therapeutic ap-
proach as it prevents renal damage caused by deposition
of C3 in the glomeruli, while leaving intact the classical
pathway for immune complex clearance and opsoniza-
tion of microbes and cellular debris.
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